Browsing Tag
AstraZeneca PLC
9 posts
Could Datroway become AstraZeneca and Daiichi Sankyo’s next major oncology franchise after Enhertu?
atroway has received a positive European regulatory recommendation for first-line treatment of metastatic triple-negative breast cancer in patients unable to receive immunotherapy. The decision moves AstraZeneca PLC and Daiichi Sankyo Company, Limited closer to opening a commercially important market while increasing the strategic value of their antibody drug conjugate partnership.
Nuvectis (NVCT) licenses two Haisco drugs as $1.46bn deal transforms its pipeline
Nuvectis licenses two Haisco drugs in a deal worth up to $1.46 billion. Find out how financing risk could reshape NVCT’s pipeline and investor outlook next.
Could Biogen and UCB finally crack one of biotech’s toughest lupus markets?
Biogen and UCB have a lupus win, but one more Phase 3 test decides the story. See why dapirolizumab pegol matters now.
AstraZeneca Q1 2026 results: Can oncology and rare disease growth keep AZN’s 2030 ambition on track?
AstraZeneca’s growth engine is firing, but pricing pressure and launch risk still loom. Can oncology and rare disease carry AZN to 2030?
Why pancreatic cancer clinicians and investors are closely watching AIM ImmunoTech’s next move
AIM ImmunoTech’s next Ampligen move could reshape pancreatic cancer treatment and investor sentiment. Find out what executives and markets are watching now.
Can fixed-duration oral therapy finally replace indefinite CLL treatment? AstraZeneca’s FDA win explains why
FDA approval of AstraZeneca’s CALQUENCE plus venetoclax introduces a fixed-duration oral option for frontline CLL. Find out why this matters for patients and investors.
Phase III evidence elevates BREZTRI in the competitive asthma landscape
Phase III data position AstraZeneca Plc’s BREZTRI for asthma growth. Discover the strategic, financial, and competitive implications.
AstraZeneca FY2025 results analysis: How oncology scale, China exposure, and pipeline depth are reshaping long-term earnings power
AstraZeneca’s FY2025 results reveal what’s driving growth, where risks are building, and how pipeline depth could shape earnings beyond 2030. Read the full analysis.
AstraZeneca, Daiichi Sankyo score tenth BTD for Enhertu in early HER2 disease
AstraZeneca and Daiichi Sankyo’s Enhertu earns FDA breakthrough tag in early breast cancer. Find out what this means for HER2 treatment strategy in 2025.